Substrate specificity-enabled terminal protection for direct quantification of circulating MicroRNA in patient serums
Li, JY (Li, Junyao)[ 1 ] ; Fu, WX (Fu, Wenxin)[ 1 ] ; Wang, ZY (Wang, Zhaoyin)[ 1 ]*(王兆寅); Dai, ZH (Dai, Zhihui)[ 1,2 ]*(戴志暉)
[ 1 ] Nanjing Normal Univ, Jiangsu Collaborat Innovat Ctr Biomed Funct Mat, Jiangsu Key Lab Biofunct Mat, Schaal Chem & Mat Sci, Nanjing 210023, Jiangsu, Peoples R China
[ 2 ] Nanjing Normal Univ, Ctr Anal & Testing, Nanjing 210023, Jiangsu, Peoples R China
CHEMICAL SCIENCE,201906,10(21),5616-5623
Currently, reported affinity pairings still lack in diversity, and thus terminal protection relying on steric hindrance is restricted in designing nucleic acid-based analytical systems. In this work, resistance to exonuclease is testified by group modification or backbone replacement, and the 3 '-phosphate group (P) reveals the strongest exonuclease I-resistant capability. Due to the substrate specificity of enzymatic catalysis, this 3 '-P protection works in a direct mode. By introducing DNA templated copper nanoparticles, an alkaline phosphatase assay is performed to confirm the 3 '-P protection. To display the application of this novel terminal protection, a multifunctional DNA is designed to quantify the model circulating microRNA (hsa-miR-21-5p) in serums from different cancer patients. According to our data, hsa-miR-21-5p-correlated cancers can be evidently distinguished from non-correlated cancers. Meanwhile, the effect of chemotherapy and radiotherapy on breast cancer is evaluated from the perspective of hsa-miR-21-5p residue in serums. Since greatly reducing the limitations of DNA design, this P-induced terminal protection can be facilely integrated with other DNA manipulations, thereby constructing more advanced biosensors with improved analytical performances for clinical applications.
文章鏈接:
https://pubs.rsc.org/en/content/articlelanding/2019/SC/C8SC05240A#!divAbstract
版權(quán)與免責(zé)聲明:本網(wǎng)頁的內(nèi)容由收集互聯(lián)網(wǎng)上公開發(fā)布的信息整理獲得。目的在于傳遞信息及分享,并不意味著贊同其觀點(diǎn)或證實(shí)其真實(shí)性,也不構(gòu)成其他建議。僅提供交流平臺,不為其版權(quán)負(fù)責(zé)。如涉及侵權(quán),請聯(lián)系我們及時(shí)修改或刪除。郵箱:sales@allpeptide.com